课题基金 / 基金详情

Molecular Regulation of Folate and Antifolate Transport

Molecular Regulation of Folate and Antifolate Transport
叶酸和抗叶酸转运的分子调节
批准号:
9025683
负责人:
Zhanjun Hou
金额:
$26.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-02-12 至 2020-02-29
关键词:
AcidsAffinityAlimtaAnionsAreaBindingBiochemicalBiologicalBiologyBloodCarrier ProteinsCell LineCellsClinicClinicalClinical TrialsCloningCoupledCytotoxinDeoxycytidineDevelopmentDietDiffusionDiseaseDrug or chemical Tissue DistributionDrug resistanceExhibitsEyeFigs - dietaryFolic AcidFolic Acid AntagonistsFosteringGene Expression RegulationGene StructureGenerationsGenetic PolymorphismGenetic TranscriptionGoalsHealthHepG2Histone Deacetylase InhibitorHomoHomology ModelingHumanHydroxymethyltransferasesImmunodeficient MouseImmunohistochemistryInheritedIntestinal AbsorptionLometrexolMalabsorption SyndromesMalignant NeoplasmsMammalian CellMediatingMembraneMesotheliomaMethotrexateMolecularMutateNeuraxisNon-Small-Cell Lung CarcinomaNucleotide BiosynthesisPatientsPemetrexedPharmaceutical PreparationsPhysiologicalPrimary NeoplasmPrimary carcinoma of the liver cellsProtonsPublishingPurine NucleotidesPyrimidineRaltitrexedReagentRegulationReporter GenesReportingResearchResistanceRibonucleotidesRoleRouteS Phase ArrestSLC19A1 geneSolid NeoplasmStructureStructure-Activity RelationshipSystemTetrahydrofolatesTherapeuticTissuesTranscriptTranscriptional RegulationTranslatingTransmembrane DomainTransmembrane TransportTumor Cell LineValproic AcidVitaminsWestern BlottingXenograft procedureabsorptionanalogbasecancer cellcancer therapyclinically relevantcofactorcytotoxicdesigndrug discoveryexperiencefolate-binding proteinfolic acid supplementationgastrointestinalglycine amidehuman tissueimprovedinsightneoplastic cellnovelnovel strategiesnovel therapeuticspolyglutamatesprophylacticprotein structure functionsmall moleculestoichiometrystructural biologytargeted cancer therapytargeted treatmenttherapeutic targettumortumor microenvironmentuptake

项目摘要

项目成果

Zhanjun Hou的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):近年来,叶酸为基础的癌症治疗再次受到重视,反映了肿瘤选择性膜转运的能力。这项应用探索了人类质子偶联叶酸转运体(HPCFT)的治疗潜力。与人还原型叶酸载体(HRFC)不同,hPCFT是一种广泛表达的组织叶酸转运蛋白,具有中性最适pH,其组织分布较窄,具有酸性最适pH的特点。HPCFT显示了在酸性PHS下的大量转运,这是肿瘤微环境的特征,而在中性pH下的转运有限。我们发现hPCFT在人类肿瘤细胞系和原发肿瘤中广泛表达。在人类肿瘤细胞中,hPCFT转录的hPCFT蛋白水平与Western blotts和转运活性平行。在人类肿瘤细胞中,hPCFT报告基因的活性与hPCFT转录本的不同水平平行。我们启动了hPCFT结构-功能研究,并在跨膜结构域(TMD2)和跨膜结构域(TMD3)之间鉴定了一个机械和结构上重要的“重入环”结构域,并在TMD2内定位了一个底物结合区。我们证明了hPCFT齐聚在功能上的重要作用,并定位了TMD6的一个重要的低聚物界面。在另一项研究中,我们鉴定了新的6-取代吡咯并[2,3-d]嘧啶硫烯酰基反叶酸酯,它们可以被hPCFT选择性地转运,但不能被HRFC转运,尽管叶酸受体的摄取也被保留了下来。这些努力培育了一种新的范式,基于主要叶酸转运体PCFT和FR的肿瘤特异性表达和/或功能,合理开发肿瘤靶向治疗。我们将继续我们的主要促进叶酸转运体的综合研究,这将对基于叶酸的癌症治疗和预防癌症的叶酸补充产生影响。我们的重点是优化我们的新型hPCFT选择性肿瘤靶向治疗方法,通过探索这种生理上重要的转运蛋白的生物学,从这一机制靶向实体肿瘤的令人信服的理论基础中得出结论。在特定的目标1中,我们将描述hPCFT靶向癌症治疗的分子和细胞决定因素,包括建立hPCFC相对于hPCFT的功能化学计量学,hPCFT和HRFC同时在肿瘤中表达的治疗影响,以及叶酸受体,以及hPCFT在人类肿瘤细胞中转录调控的机制。在目标2中,我们将描述hPCFT靶向治疗的结构和功能决定因素,包括hPCFT蛋白中重要的功能结构域和残基的鉴定,以及hPCFT同源寡聚体的结构、功能和调节特性。我们的目标是利用hPCFT结构和功能的生化研究和分子同源性建模,帮助我们的药物开发工作,并寻找新的方法来提高hPCFT选择性药物的肿瘤靶向性和疗效。我们提出的研究得到了我们的初步和已发表的结果以及关键试剂和细胞系的有力支持,其中包括第一代特异和有效的hPCFT选择性肿瘤靶向抗叶酸盐,这些抗叶酸不是由HRFC转运的。我们的研究是独特的,因为它们的新颖性和可能性为这些生理和药理上重要的维生素转运蛋白的机制和调节提供了关键的新见解,可以转化到临床上。
英文摘要
DESCRIPTION (provided by applicant): In recent years, there has been renewed emphasis on folate-based therapeutics for cancer, reflecting on capacities for tumor-selective membrane transport. This application explores the therapeutic potential for the human proton-coupled folate transporter (hPCFT). Unlike the human reduced folate carrier (hRFC), the major tissue folate transporter which is ubiquitously expressed and has a neutral pH optimum, hPCFT shows a narrower tissue distribution and is characterized by an acid pH optimum. hPCFT shows substantial transport at acid pHs characterizing the tumor microenvironment and limited transport at neutral pH. We showed that hPCFT is widely expressed in human tumor cell lines and primary tumors. In human tumor cells, hPCFT transcripts paralleled levels of hPCFT proteins on Western blots and transport activity. In human tumor cells, hPCFT reporter gene activity paralleled disparate levels of hPCFT transcripts. We initiated hPCFT structure-function studies and characterized a mechanistically and structurally important "re-entrant loop" domain between transmembrane domains (TMDs) 2 and 3 and localized a substrate binding region within TMD2. We demonstrated a functionally important role for hPCFT oligomerization and localized an important oligomer interface to TMD6. In a separate line of study, we identified novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates that are selectively transported by hPCFT but not hRFC, although uptake by folate receptor was also preserved. These efforts have fostered a new paradigm, the rational development of tumor-targeted therapies based on tumor-specific expression and/or function of the major folate transporters, PCFT and FR. We will continue our comprehensive study of the major facilitative folate transporters, with implications to folate-based therapies for cancer, and to prophylactic folate supple- mentation for cancer. Our emphasis is on optimizing our novel hPCFT-selective therapeutics for tumor targeting, by exploring the biology of this physiologically important transporter, drawing from a compelling rationale for targeting solid tumors by this mechanism. In Specific Aim 1, we will characterize molecular and cellular determinants of hPCFT- targeted cancer therapy, including establishing functional stoichiometries for hRFC vis a vis hPCFT, the therapeutic impact of concomitant tumor expression of hPCFT and hRFC, as well as folate receptor , and mechanisms of hPCFT transcriptional regulation in human tumor cells. In Aim 2, we will characterize structural and functional determinants of hPCFT-targeted therapy, including identification of functionally important domains and residues in the hPCFT protein, and the structural, functional, and regulatory features of hPCFT homo-oligomers. The goal is to use biochemical studies of hPCFT structure and function, and molecular homology modeling, to assist our drug discovery efforts, and to identify new approaches to enhance tumor targeting and efficacy of hPCFT-selective drugs. Our proposed studies are strongly supported by our preliminary and published results and the availability of critical reagents and cell lines, includig the first generation of specific and potent hPCFT-selective tumor-targeted antifolates that are not transported by hRFC. Our studies are distinctive for their novelty and likelihood of providing critical new insights into mechanisms and regulation of these physiologically and pharmacologically important vitamin transporters that can be translated to the clinic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biology of major folate transporters and STING signaling in cancer
  • 批准号:
    10597540
  • 项目类别:
  • 资助金额:
    $7.7万
  • 财政年份:
    2022
  • 负责人:
    Zhanjun Hou
  • 依托单位:
Biology of major folate transporters and STING signaling in cancer
  • 批准号:
    10435010
  • 项目类别:
  • 资助金额:
    $7.7万
  • 财政年份:
    2022
  • 负责人:
    Zhanjun Hou
  • 依托单位:
Molecular Regulation of Folate and Antifolate Transport
  • 批准号:
    10652998
  • 项目类别:
  • 资助金额:
    $29.26万
  • 财政年份:
    1993
  • 负责人:
    Zhanjun Hou
  • 依托单位:
Molecular Regulation of Folate and Antifolate Transport
  • 批准号:
    10438789
  • 项目类别:
  • 资助金额:
    $28.67万
  • 财政年份:
    1993
  • 负责人:
    Zhanjun Hou
  • 依托单位:
海外基金